Prospectus Filed Pursuant to Rule 424(b)(3) (424b3)

PROSPECTUS SUPPLEMENT NO. 5 Filed Pursuant to Rule 424(b)(3)

(to prospectus dated August 5, 2021.) Registration No. 333-258325

Up to 53,211,039 Shares of Common Stock

This prospectus supplement no. 5 (this “prospectus supplement”) amends and supplements the prospectus dated August 5, 2021 (as supplemented or amended from time to time, the “Prospectus”) which forms a part of our Registration Statement on Form S-1 (Registration Statement No. 333-258325). This prospectus supplement is being filed to update and supplement the information included or incorporated by reference in the Prospectus with the information contained in our Current Report on Form 8-K, filed with the Securities and Exchange Commission (the “SEC”) on December 10, 2021 (the “Form 8-K”). Accordingly, we have attached the Form 8-K to this prospectus supplement.

This prospectus supplement updates and supplements the information in the Prospectus and is not complete without, and may not be delivered or utilized except in combination with, the Prospectus, including any amendments or supplements thereto. This prospectus supplement should be read in conjunction with the Prospectus and if there is any inconsistency between the information in the Prospectus and this prospectus supplement, you should rely on the information in this prospectus supplement.

Our common stock is listed on The NASDAQ Stock Market LLC under the symbols “PNT”. On December 8, 2021, the closing price of our common stock was $6.48 per share.

Investing in our securities involves risks that are described in the “Risk Factors” section beginning on page 13 of the Prospectus.

Neither the SEC nor any state securities commission has approved or disapproved of the securities to be issued under the Prospectus or determined if the Prospectus or this prospectus supplement is truthful or complete. Any representation to the contrary is a criminal offense.

The date of this prospectus supplement is December 10, 2021.

31930443.1

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported): December 10, 2021 (December 9, 2021)

_______________________

POINT BIOPHARMA GLOBAL INC.

(Exact name of registrant as specified in its charter)

_______________________


Delaware (State or other jurisdiction of incorporation)	001-39311 (Commission File Number)	85-0800493 (I.R.S. Employer Identification No.)
4850 West 78th Street, Indianapolis, IN, 46268
(Address of principal executive offices and zip)

(647) 812-2417

Registrant’s telephone number, including area code

(Former name or former address, if changed since last report)

_______________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common stock, par value $0.0001 per share	PNT	The Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

Information responsive to Item 5.02(e):

Effective December 9, 2021, the Compensation Committee of the Board of Directors (the “Committee”) of POINT Biopharma Global Inc. (the “Company”), pursuant to Section 2(b) of the Company’s 2021 Equity Incentive Plan (the “2021 Plan”), provided that all stock options previously granted under the 2021 Plan and still outstanding would automatically become fully vested and exercisable as of the effective time of a Sale Event (as defined in the 2021 Plan). Each of the Company’s named executive officers currently has outstanding stock options that are impacted by this action.

In addition, the Committee approved the revised form of option agreements to be used by the Company in future grants of stock options to provide that upon any Sale Event, the stock options granted under the 2021 Plan and still outstanding shall automatically become fully vested and exercisable as of the effective time of the Sale Event. The revised form of option agreements are filed as Exhibits 10.1, 10.2 and 10.3 to this Form 8-K.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

Number Exhibit

10.1 Revised Form of Non -Qualified Stock Option Agreement under the POINT Biopharma Globa l Inc. 2021 Equity Ince ntive Plan (Employees).

10.2 Revised Form of Non-Qualified Stock Option Agreement under the POINT Biopharma Global Inc. 2021 Equity Incentive Plan (Directors ).

10.3 Revised Form of Incent ive Stock Option Agreement under the POINT Biopharma Global Inc. 2021 Equity Incentive Plan .

104 Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.